Kidney Disease
10 videos · last 6 months shuffled daily, then older videos newest first
▶
5:30 Non-Dialytic Care vs. Dialysis in Veterans With Advanced CKD
Onnie M. Rhee of the VA Greater Los Angeles on her Mayo Clinic Proceedings study of veterans with advanced kidney disease, which found higher hospitalization rates with dialysis than with non-dialytic care.
▶
1:03:42 Surrogate Endpoints in Kidney Disease: What They Mean for Patient Access
A CAPT-ACTP 2026 conference panel examines surrogate endpoints in trials for immune-mediated glomerular diseases and how health technology assessment treats that evidence when deciding reimbursement and patient access.
▶
8:38 Real-World Insights on the Treatment of Hyperkalemia
Biff F. Palmer, MD, of Texas Tech reviews a Renal Physicians Association consensus meeting on treating hyperkalemia, in the July 2026 issue of Mayo Clinic Proceedings.
▶
6:02 Continuing RAASi in ICU Admitted Patients
Ruey-Hsing Chou, MD, PhD, on a matched cohort comparing ICU patients who continued renin-angiotensin-aldosterone system inhibitors against those switched to other antihypertensives.
▶
18:27 The CKM Score in Clinical Trial Design
Dr. Carine Hamo, Dr. Ankeet Bhatt and Dr. Javed Butler discuss the CKM score and the quantitative methods beginning to change how clinical trials are designed and conducted, on the CardioPod podcast.
▶
56:46 Kidney Disease Clinical Trials: Lived Experiences
Grant Bonebrake, Lisa Bonebrake, Jill Goodrich and Curtis Warfield discuss the experiences of patients, caregivers and advocates in kidney disease clinical trials, barriers that limit diversity, and supports participants may encounter, for kidneyfund.
▶
50:54 REGENCY: Obinutuzumab in Lupus Nephritis
Brad Rovin, MD, of Ohio State University Wexner Medical Center and Ana Malvar, MD, of Hospital Fernandez in Buenos Aires present the background and central results of the phase 3 REGENCY study of obinutuzumab in active lupus nephritis, for MARKUS at HOMe.
▶
6:05 Accelerated Approval for Atrasentan in IgAN
Nephrology Times on the FDA's April 2025 accelerated approval of atrasentan, marketed by Novartis as Vanrafia, for reducing proteinuria in adults with primary IgA nephropathy.
▶
4:24 Kidney Biopsies in C3G Trial Design
A Nephrology Times roundtable with Cybele Ghossein, MD (Northwestern Medicine), Anthony Chang, MD (University of Chicago), Fernando Fervenza, MD, PhD (Mayo Clinic) and others discusses kidney biopsies in the C3G trials of iptacopan and pegcetacoplan.
▶
10:21 KOAR Study Highlights Promise of dd-cfDNA in Kidney Transplant
Nephrology Times on the KOAR study, published in the American Journal of Transplantation — the largest prospective study of donor-derived cell-free DNA in kidney transplant monitoring.